Genentech, Inc. (NYSE: DNA) has collected a respectable gain of 15% during the past 52 weeks, and the shares have bounced more than 20% higher from their Dec. 2 low near the 71 level. The equity's latest upswing has been underscored by support from its 10-day and 50-day moving averages, although resistance in the 88 region continues to stifle the shares' progress.
The stock extended its gains last week, when DNA's board rejected a hostile takeover bid from major stakeholder Roche Holding AG. As investors placed their bets on a sweetened buyout offer from Roche, call volume accelerated on the shares of Genentech.
To continue reading this article, click here: http://www.schaeffersresearch.com/commentary/content/call+volume+swarms+genentech+inc+as+the+shares+battle+resistance/observations.aspx?click=home&ID=91475&source=businesswire